Local startup Metactive Medical Inc. recently closed a Series A round that raised $2 million.

The Kansas Bioscience Authority, which has previously invested in Metactive Medical, led the round. To date, the startup has raised $7 million.

The money will allow Metactive to keep working on embolic devices that are used to treat aneurysms. These tiny instruments can be used to stop blood flow in damaged veins and arteries and keep blood away from tumors.

“Clinicians treat thousands of saccular aneurysms and peripheral arteries and veins each year,” said Tom Krol, managing director of the Kansas Bioscience Authority and a member of Metactive’s board. “We believe that Metactive’s devices have the potential to be better for patients, faster and easier for physicians to use, and less expensive for payers.”

Metactive also said that it had added David Ferrera, the president and chief technology officer of Blockade Medical, to its board of directors. He has a long history of working with medical devices, including ones that focus on neurovascular applications.

“I am pleased to have the resources to accelerate the development of our novel, potentially life-saving products and to welcome David to our board to help us realize our goal of providing physicians faster, better and less expensive options for vascular occlusion,” said F. Nicholas Franano, president and CEO of Metactive.